Skip to main content
Find more clinical trials

AL001 for Frontotemporal Dementia in Healthy Volunteers and People with FTD

Start: September 14, 2018
End: December 31, 2019
Enrollment: 60

What Is This Study About?

This Phase 1 study is testing the investigational drug AL001 as a possible treatment for frontotemporal dementia (FTD) in healthy volunteers and people with FTD who also have a granulin mutation (PGRN).

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 80 Years

Must have:

  • BMI 18 to 35
  • Weight 99 to 265 lbs
  • Not pregnant or lactating
  • Females of childbearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit
  • No significant findings on medical history, physical exam, laboratory tests, electrocardiogram, or other tests

Must NOT have:

  • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to antibodies or fusion proteins
  • Positive drug or alcohol at screening and prior to first dose
  • History of alcohol or substance abuse

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Alector Inc.

Source: ClinicalTrials.gov ID: NCT03636204